Free 7-day Trial
All Articles and Columns »

CFO of Merck & Co. Peter Kellogg Buys 15,800 Shares

August 15, 2011 | About:
GuruFocus

hyperman299

4 followers
Executive Vice President & CFO of Merck & Co. Inc. (MRK) Peter N. Kellogg bought 15,800 shares on 08/12/2011 at an average price of $31.8. The total transaction amount is $502,440. Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck & Co. Inc. has a market cap of $96.73 billion; its shares were traded at around $31.2 with a P/E ratio of 8.71 and P/S ratio of 2.1. The dividend yield of Merck & Co. Inc. stocks is 4.85%.

HOTCHKIS & WILEY owns 6,140,469 shares as of 03/31/2011, an increase of 896.03% from the previous quarter. This position accounts for 1.13% of the $17.91 billion portfolio of Hotchkis & Wliey Capital Management LLC. Joel Greenblatt owns 89,085 shares as of 06/30/2011, an increase of 376.87% from the previous quarter. This position accounts for 0.4395% of the $715 million portfolio of Gotham Capital. Charles Mark Hillman owns 37,444 shares as of 03/31/2011, a decrease of 29.34% of from the previous quarter. This position accounts for 0.3% of the $415 million portfolio of Hillman Capital Management. George Soros sold out his holdings in the quarter that ended on 06/30/2011.

Mr. Peter N. Kellogg has been chief financial officer and executive vice president of Merck & Co. Inc. since Aug. 14, 2007. Mr. Kellogg served as an executive vice president of finance and chief financial officer of Biogen Idec Inc. since November 2003 and served as its Principal Accounting Officer until December 2006. Mr. Kellogg served as an executive vice president of finance and chief financial officer of finance of Biogen Inc. since October 2001. He received a B.S.E. from Princeton University in 1978 and an M.B.A. from The Wharton School in 1982.

Worldwide sales were $12.2 billion for the second quarter of 2011, the highest quarterly sales total for the combined company and an increase of 7 percent compared with the second quarter of 2010. Foreign exchange for the quarter favorably affected global sales performance by 4 percent. The revenue increase largely reflects strong sales of several drugs. Pharmaceutical sales from emerging markets accounted for 18 percent of sales in the quarter.

Executive Vice President & CFO Peter N. Kellogg bought 15,800 shares of MRK stock on 08/12/2011 at the average price of $31.8. Peter N. Kellogg owns at least 53,999 shares after this. The price of the stock has decreased by 1.89% since. Executive Vice President & President Animal Health Raul E. Kohan sold 63,881 shares of MRK stock on 05/18/2011 at the average price of 37.21. Raul E. Kohan owns at least 82,662 shares after this. The price of the stock has decreased by 16.15% since. Executive Vice President & Chief Comp. Officer Richard S. Bowles III sold 29,755 shares of MRK stock on 05/04/2011 at the average price of $36.56. Richard S. Bowles III owns at least 80,419 shares after this. The price of the stock has decreased by 14.66% since.

Merck & Co. has a predictability rating of 1 star.

Rating: 2.7/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide